Study Description
The objective of this study is to evaluate the long-term safety of Leqvio in patients with familial hypercholesterolaemia or hypercholesterolaemia in post-marketing clinical practice
Uncontrolled, central registration system, multicenter, special drug use-results surveillance.
This is a prospective, open-label, multicenter, single-arm observational study (non-interventional study: NIS) conducted only in Japan.
The survey will include patients with familial hypercholesterolaemia or hypercholesterolaemia who have received treatment with Leqvio. Patients who discontinued treatment with Leqvio before completing the 24-month observation period will be followed for safety until the date of the last dose of Leqvio plus 180 days or until 24 months after the first dose of Leqvio, whichever comes earlier.
Interventions
inclisiran
Eligibility Criteria
Inclusion Criteria:
Patients who provided written informed consent to participate in this survey prior to the start of treatment with Leqvio.
Patients who received treatment with Leqvio as per the package insert.
Exclusion Criteria:
Patients who received treatment with a formulation containing the same ingredients as Leqvio in the past.
Patients participating in other interventional studies at the time of informed consent.
Patients planning to participate in other interventional studies during this survey.
Study Location
Novartis Investigative Site
Recruiting
Handa,Aichi,475-0817,Japan
Novartis Investigative Site
Recruiting
Osaka-city,Osaka,543-8555,Japan
Novartis Investigative Site
Recruiting
Machida,Tokyo,194-0021,Japan
Novartis Investigative Site
Recruiting
Toshima-ku,Tokyo,171-0014,Japan
Novartis Investigative Site
Recruiting
Ikoma,Nara,636-0802,Japan
Novartis Investigative Site
Recruiting
Osaka,545-8586,Japan
Novartis Investigative Site
Recruiting
Matsuyama,Ehime,791-8016,Japan
Novartis Investigative Site
Recruiting
Toyonaka,Osaka,560-0083,Japan
Novartis Investigative Site
Recruiting
Kanazawa-city,Ishikawa,920-8641,Japan
Novartis Investigative Site
Recruiting
Sapporo,Hokkaido,004-0052,Japan
Novartis Investigative Site
Recruiting
Nagasaki,852-8055,Japan
Novartis Investigative Site
Recruiting
Urasoe,Okinawa,901-2102,Japan
Novartis Investigative Site
Recruiting
Kashihara,Nara,634-0045,Japan
Novartis Investigative Site
Recruiting
Takaoka,Toyama,939-1104,Japan
Novartis Investigative Site
Recruiting
Nerima-ku,Tokyo,176-8530,Japan
Novartis Investigative Site
Recruiting
Yokohama,Kanagawa,235-0016,Japan
Novartis Investigative Site
Recruiting
Kitakyushu,Fukuoka,800-0031,Japan
Novartis Investigative Site
Recruiting
Takarazuka-city,Hyogo,665-0873,Japan
Novartis Investigative Site
Recruiting
Asahikawa,Hokkaido,078-8214,Japan
Novartis Investigative Site
Recruiting
Oita,870-1133,Japan
Novartis Investigative Site
Recruiting
Kobe,Hyogo,654-0026,Japan
Novartis Investigative Site
Recruiting
Takatsuki-city,Osaka,569-0852,Japan
Novartis Investigative Site
Recruiting
Fukuoka,815-0082,Japan
Novartis Investigative Site
Recruiting
Oita,879-7761,Japan
Novartis Investigative Site
Recruiting
Kurashiki,Okayama,713-8121,Japan
Novartis Investigative Site
Recruiting
Takatsuki-city,Osaka,569-8686,Japan
Worldwide Contacts
If the location of your choosing does not feature any contact detail, please reach out using the information below.